{"prompt": "['Novartis', 'Confidential', 'Page 60', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'of the study drug will be classified as a prior adverse event and not included in tabulations of', 'treatment emergent adverse events.', 'The following treatment emergent adverse event summaries will be produced,', 'overall by system organ class and preferred term,', 'overall by system organ class and preferred,', 'overall by system organ class, preferred term and maximum severity,', 'suspected drug related adverse events by system organ class and preferred term, and', 'adverse events leading to permanent discontinuation of study drug by system organ class', 'and preferred term.', 'Serious adverse events, non-serious adverse events, adverse events requiring dose adjustment', 'or study-drug interruption adverse events requiring additional therapy during the on-treatment', 'period will be summarized.', 'The adverse events of special interest (AESI) will be listed and summarized by treatment group.', 'Vital signs', 'All vital signs data will be listed by treatment group, On-treatment notable vital signs', 'abnormalities will be summarized by treatment group.', '12-lead ECG', 'The notable ECG abnormalities will be summarized for following ECG variables,QT interval,', \"RR interval, PR interval, QRS duration, heart rate, and Friedericia's QTc.\", 'Clinical laboratory evaluations', 'All laboratory data will be listed with abnormal values flagged.', 'All laboratory parameter values will be classified into one of the four mutually exclusive groups', '(low, normal, high, and low + high).', 'For selected laboratory parameters, the number and percentage of patients with newly occurring', 'or worsening on-treatment laboratory abnormalities meeting the clinically notable will be', 'summarized by laboratory parameter at any time-point over the treatment period, considering', 'all post-baseline data from scheduled, unscheduled and premature discontinuation visits.', 'Patients with any newly occurring or worsening on-treatment value meeting the clinically', 'notable criteria will be counted under the applicable criteria.', '12.7', 'Interim analyses', 'No formal interim analysis will be performed in this trial.']['Novartis', 'Confidential', 'Page 61', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '12.8', 'Sample size calculation', '12.8.1', 'Primary endpoint(s)', 'Based on clinical judgement a mean reduction of 1.5 in polyp score (as measured by the', 'NPS) can be expected with fevipiprant (450 mg and 150 mg) and SoC as compared to Placebo', 'and SoC. Considering this factor, the sample size was calculated under an 80% power and 1.25%', 'one sided alpha for comparison of each of the two dose levels of fevipiprant and SoC with', 'placebo and SoC. A 10% dropout rate is considered as appropriate with reference to prior', 'studies (omalizumab study by Gevaert et al 2013 and dupilumab study by Bachert et al 2016).', 'From prior literature standard deviation of 1.8 is considered as appropriate for the change of', 'score from baseline at 16 weeks in Nasal Polyp Score.', 'The sample size calculation was performed using the software PASS 2008 using inequality tests', 'using difference of two independent means with equal variance.', 'The randomization will be performed in a 1:1:1 ratio for the two separate doses level of', 'fevipiprant (450 mg and 150 mg) and the placebo arm. Under these assumptions (effect size =', '1.5, equal SD = 1.8,power = 80% for each arm individually, one-sided alpha = 0.0125 and', 'dropout = 10%), the total sample size yielded was 93 with 31 patients in each arm.', 'The sample size provides a power of 80% for each comparison but since we will be testing', \"correlated hypothesis using a Dunnet's test, this is a lower bound on the power. The real power\", 'is expected to be higher if in at least one of the 2 dosages i.e. fevipiprant 150 mg or fevipiprant', '450 mg, the standardized effect size (in other words, keeping the assumption of an SD of 1.8 in', 'each group) is equal to the clinically significant value of 1.5 and there is some treatment benefit', 'in the other groups as well. However, if the effect size is equal to 1.5 in both of the groups, the', 'power will be substantially higher i.e. around 93%', '13', 'Ethical considerations and administrative procedures', '13.1', 'Regulatory and ethical compliance', 'This clinical study was designed and shall be implemented, executed and reported in accordance', 'with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable', 'local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical', 'principles laid down in the Declaration of Helsinki.', '13.2', 'Responsibilities of the investigator and IRB/IEC', 'Before initiating a trial, the Investigator/institution must obtain approval/favorable opinion from', 'the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial protocol,', 'written informed consent form, consent form updates, subject recruitment procedures (e.g.,', 'advertisements) and any other written information to be provided to subjects. Prior to study', 'start, the Investigator is required to sign a protocol signature page confirming his/her agreement', 'to conduct the study in accordance with these documents and all of the instructions and', 'procedures found in this protocol and to give access to all relevant data and records to', 'Novartis monitors, auditors, Novartis Quality Assurance representatives, designated agents of', 'Novartis, IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site']\n\n###\n\n", "completion": "END"}